Cytogen, Inc. (KOSDAQ:217330)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,710.00
+130.00 (2.33%)
At close: Apr 28, 2026
31.72%
Market Cap 131.73B
Revenue (ttm) 26.05B
Net Income (ttm) -12.34B
Shares Out 23.07M
EPS (ttm) -535.00
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 569,446
Average Volume 381,618
Open 5,600.00
Previous Close 5,580.00
Day's Range 5,450.00 - 5,830.00
52-Week Range 2,260.00 - 11,200.00
Beta -0.03
RSI 65.49
Earnings Date May 15, 2026

About Cytogen

Cytogen, Inc., a biotechnology company, engages in blood cancer cell-based Liquid Biopsy application business in South Korea. The company offers cell isolators that enrich CTCs from human blood and/or body fluid using high density microporous chips; IF stainers, automated immunofluorescent staining system; and cell image analyzers, which help captures immunofluorescent images of cells stained with anti-EpCAM, -CD45, and CK antibodies. The company sells its products under the Smart Biopsy brand name. Cytogen, Inc. was founded in 2010 and is head... [Read more]

Industry In Vitro and In Vivo Diagnostic Substances
Founded 2010
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 217330
Full Company Profile

Financial Performance

In 2025, Cytogen's revenue was 26.05 billion, an increase of 138.80% compared to the previous year's 10.91 billion. Losses were -12.34 billion, -27.89% less than in 2024.

Financial Statements

News

There is no news available yet.